National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.
Viruses. 2023 Jan 13;15(1):219. doi: 10.3390/v15010219.
Genital herpes (GH) has become one of the most common sexually transmitted diseases worldwide, and it is spreading rapidly in developing countries. Approximately 90% of GH cases are caused by HSV-2. Therapeutic HSV-2 vaccines are intended for people already infected with HSV-2 with the goal of reducing clinical recurrences and recurrent virus shedding. In our previous work, we evaluated recombinant adenovirus-based vaccines, including rAd-gD2ΔUL25, rAd-ΔUL25, and rAd-gD2, for their potency as prophylactic vaccines. In this study, we evaluated these three vaccines as therapeutic vaccines against acute and recurrent diseases in intravaginal challenged guinea pigs. Compared with the control groups, the recombinant vaccine rAd-gD2ΔUL25 induced a higher titer of the binding antibody, and rAd-gD2 + rAd-ΔUL25 induced a higher titer of the neutralizing antibody. Both rAd-gD2ΔUL25 and rAd-gD2 + rAd-ΔUL25 vaccines significantly enhanced the survival rate by 50% compared to rAd-gD2 and reduced viral replication in the genital tract and recurrent genital skin disease. Our findings provide a new perspective for HSV-2 therapeutic vaccine research and provide a new technique to curtail the increasing spread of HSV-2.
生殖器疱疹（GH）已成为全球最常见的性传播疾病之一，在发展中国家迅速传播。大约 90%的 GH 病例由 HSV-2 引起。治疗性 HSV-2 疫苗旨在针对已感染 HSV-2 的人群，目标是减少临床复发和复发性病毒脱落。在我们之前的工作中，我们评估了基于重组腺病毒的疫苗，包括 rAd-gD2ΔUL25、rAd-ΔUL25 和 rAd-gD2，以评估其作为预防性疫苗的效力。在这项研究中，我们评估了这三种疫苗作为治疗性疫苗对阴道内挑战豚鼠急性和复发性疾病的疗效。与对照组相比，重组疫苗 rAd-gD2ΔUL25 诱导了更高滴度的结合抗体，而 rAd-gD2+rAd-ΔUL25 诱导了更高滴度的中和抗体。与 rAd-gD2 相比，rAd-gD2ΔUL25 和 rAd-gD2+rAd-ΔUL25 疫苗均使存活率显著提高了 50%，并减少了生殖道中的病毒复制和复发性生殖器皮肤疾病。我们的研究结果为 HSV-2 治疗性疫苗研究提供了新的视角，并为遏制 HSV-2 的传播提供了新的技术。
